We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03336580
Recruitment Status : Terminated (Because of the impact of COVID-19 pandemic)
First Posted : November 8, 2017
Last Update Posted : August 20, 2020
Sponsor:
Information provided by (Responsible Party):
Prothena Biosciences Limited

Tracking Information
First Submitted Date  ICMJE October 23, 2017
First Posted Date  ICMJE November 8, 2017
Last Update Posted Date August 20, 2020
Actual Study Start Date  ICMJE April 5, 2018
Actual Primary Completion Date July 23, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: September 7, 2018)
  • Maximum Tolerated Dose of PRX004 [ Time Frame: 28 days ]
    Maximum Tolerated Dose of PRX004
  • Number of subjects with treatment-emergent adverse events and clinically significant changes in ECGs, echocardiograms, cardiac telemetry, vital signs, and laboratory evaluations [ Time Frame: 3 months ]
    Number of subjects with treatment-emergent adverse events and clinically significant changes in ECGs, echocardiograms, cardiac telemetry, vital signs, and laboratory evaluations
Original Primary Outcome Measures  ICMJE
 (submitted: November 3, 2017)
Maximum tolerated dose (MTD) of PRX004 in subjects with hATTR amyloidosis [ Time Frame: 18 months ]
To determine the maximum tolerated dose (MTD) of PRX004 in subjects with hATTR amyloidosis
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: December 14, 2018)
  • PRX004 pharmacokinetic parameters - Cmin [ Time Frame: 3 months ]
    Minimum observed concentration (Cmin) of PRX004 in plasma
  • PRX004 pharmacokinetic parameters -Cmax [ Time Frame: 3 months ]
    Maximum observed concentration (Cmax) of PRX004 in plasma
  • PRX004 pharmacokinetic parameters - T1/2 [ Time Frame: 3 months ]
    Terminal elimination half-life (T1/2) of PRX004 in plasma
  • PRX004 pharmacokinetic parameters -AUClast [ Time Frame: 3 months ]
    Area under the concentration-time curve from time zero to the last quantifiable concentration time-point (AUClast) of PRX004 in plasma
  • PRX004 pharmacokinetic parameters -AUCtau [ Time Frame: 3 months ]
    Area under the concentration-time curve over the dosing interval (AUCtau) of PRX004 in plasma
  • Immunogenicity indicators [ Time Frame: 3 months ]
    Immunogenicity indicators: Anti-drug antibodies (ADAs)
Original Secondary Outcome Measures  ICMJE
 (submitted: November 3, 2017)
Safety, of the anticipated RP2D(s) of PRX004 in subjects with hATTR or wtATTR amyloidosis [ Time Frame: 18 months ]
To identify the safety of the anticipated Recommended Phase 2 Dose of PRX004 in subjects with hATTR or wtATTR amyloidosis as assessed by the CTCAE Criteria for Adverse Events (CTCAE) Grade 1-5
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis
Official Title  ICMJE A Phase 1, Open-label, Dose Escalation Study of Intravenous PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis
Brief Summary A Phase 1, open-label study of intravenous (IV) PRX004 as a single agent in subjects with hereditary amyloid transthyretin (hATTR) amyloidosis. The study will consist of 3 phases and will enroll up to a total of 36 subjects. A 3+3 dose escalation component to determine the safety, tolerability, PK, PD, and MTD. An expansion component in anticipated PRX004 RP2D cohorts selected from the Dose Escalation Phase. An extended dosing component for eligible subjects from the Dose Escalation or Expansion phases.
Detailed Description

This Phase 1, open-label consists of 3 phases. The Dose Escalation Phase is a 3+3 dose escalation component to determine the safety, tolerability, PK, PD, and MTD of IV PRX004 when given as a single agent in up to 36 evaluable subjects with hATTR amyloidosis. The Expansion Phase is an expansion component in anticipated PRX004 RP2D cohorts selected from the Dose Escalation Phase (this may occur in addition to cohorts in which additional subjects were added due to the observation of a dose-limiting [DLT] in the Escalation Phase). The Long-term Extension (LTE) Phase is an extended dosing component for eligible subjects from the Dose Escalation or Expansion phases.

The Dose Escalation Phase will follow a standard 3+3 design, in which cohorts of 3 to 6 subjects with hATTR amyloidosis will be enrolled at each dose level to receive IV PRX004 once every 28 days, based on scheduling from Month 1-Day 1 for up to 3 doses. Each subject will participate in only 1 dose escalation cohort. The starting dose of PRX004 will be 0.1 mg/kg.

Dose escalation will occur after the third evaluable subject in a cohort has completed the first 28 days following the first administration of PRX004. Up to 6 dose levels of PRX004 may be investigated (0.1, 0.3, 1, 3, 10, and 30 mg/kg) if tolerable. In the event the starting dose of 0.1 mg/kg is not tolerated, the dose escalationwill be halted and the study stopped.

Each subject will receive a maximum of 3 infusions of PRX004 in the Dose Escalation Phase. Subjects who complete the Month 3-Day 22 Visit in the Dose Escalation or Expansion phases may be eligible to receive up to 15 additional PRX004 infusions in the LTE Phase.

Each subject will receive a maximum of 3 infusions of PRX004 in the Dose Escalation Phase. Subjects who complete the Month 3-Day 22 Visit in the Dose Escalation or Expansion phases may be eligible to receive up to 15 additional PRX004 infusions in the LTE Phase.

Subjects who completed the EOS Visit in the Dose Escalation Phase prior to implementation of Protocol Amendment 2 may re-enter the study in the LTE Phase if they meet specific inclusion/exclusion criteria.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:
Dose Escalation Study
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Amyloidogenic Transthyretin (ATTR) Amyloidosis
Intervention  ICMJE Drug: PRX004

PRX004 (0.1, 0.3, 1, 3, 10, and 30 mg/kg) IV every 28 days

PRX004 IV every 28 days at RP2D(s)

PRX004 IV every 28 days at RP2D(s)

Study Arms  ICMJE Experimental: PRX004

Dose escalation in up to 6 dose levels

Expansion of previously studied cohort(s) from Dose Escalation

Extended dosing at RP2D

Intervention: Drug: PRX004
Publications * Capustin M, Frishman WH. Transthyretin Cardiac Amyloidosis and Novel Therapies to Treat This Not-so-rare Cause of Cardiomyopathy. Cardiol Rev. 2021 Sep-Oct 01;29(5):263-273. doi: 10.1097/CRD.0000000000000387. Review.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: June 4, 2020)
21
Original Estimated Enrollment  ICMJE
 (submitted: November 3, 2017)
36
Actual Study Completion Date  ICMJE July 23, 2020
Actual Primary Completion Date July 23, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Age ≥18 years
  2. Ability to understand and willingness to sign an informed consent form prior to initiation of any study procedures
  3. Diagnosis of amyloidosis determined by polarizing light microscopy of green birefringent material in Congo Red-stained tissue specimens; and confirmed diagnosis of ATTR amyloidosis by immunohistochemistry, mass spectrometry, documentation of an ATTR mutation by gene sequencing, or 99m technetium-3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) scans and/or technetium pyrophosphate (PYP) SPECT cardiac imaging. If scintigraphy is used for diagnosis then the grade must be 2 or greater, indicative of transthyretin amyloidosis-cardiomyopathy (ATTR-CM) (Gillmore, 2016)
  4. Known TTR mutation
  5. [Inclusion Criterion 5 removed in Amendment 2]
  6. Patients receiving concomitant tafamidis or diflunisal may enroll in the study, providing the dose has been stable for the last 6 months
  7. Karnofsky Performance Status (KPS) ≥60%
  8. Adequate organ function, including all of the following:

    1. Adequate bone marrow reserve, defined as the following: absolute neutrophil count ≥1.0 × 109/L; platelet count ≥100 × 109/L; hemoglobin ≥10 g/dL
    2. Hepatic: total bilirubin ≤ 2 times the upper limit of normal (× ULN), transaminases (aspartate aminotransferase and/or alanine aminotransferase) ≤3 × ULN; alkaline phosphatase ≤5 × ULN
    3. Renal: estimated glomerular filtration rate (eGFR) ≥45 mL/min/1.73 m2
  9. If currently receiving a diuretic, must have been on a stable dose for at least 4 weeks prior to the first dose of study drug
  10. Systolic blood pressure ≥90 mmHg and ≤180 mmHg
  11. Subjects with cardiomyopathy must have an NT-proBNP ≥650 pg/mL and ≤5000 pg/mL (ie, ≥76.9 pmol/L and ≤591 pmol/L) or evidence of septal wall thickening >1.2 cm on echocardiogram
  12. Must have a biopsy unless data are available from a previous one. The biopsy may be taken from any tissue or organ affected by ATTR amyloidosis (eg, skin, lip, abdominal fat pad, salivary gland), at the Investigator's discretion. Nerve biopsies are not required.
  13. Women of childbearing potential must have 2 negative pregnancy tests during Screening, the second within 24 hours prior to the first administration of study drug, and must agree to use highly effective physician-approved contraception from Screening to 90 days following the last study drug administration
  14. Male subjects must be surgically sterile or must agree to use highly effective physician-approved contraception from Screening to 90 days following the last study drug administration
  15. Polyneuropathy Disability (PND) Score ≤IIIB
  16. Neuropathy Impairment Score (NIS) ≥5 and ≤130

Exclusion Criteria:

  1. Amyloid light chain or other non-ATTR amyloidosis
  2. Any past history of or present abuse of alcohol, diabetes, B12 or folate deficiencies, autoimmune diseases, hereditary disorders other than transthyretin (eg, Charcot-Marie-Tooth), uncontrolled hypothyroidism, or other etiologies for the peripheral neuropathy
  3. Received prior liver transplant
  4. Planned liver transplant during the study
  5. Modified body mass index (mBMI) ≤600 kg/m2 × g/L
  6. New York Heart Association (NYHA) Functional Class III-IV (Appendix 2)
  7. LVEF ≤45%
  8. Uncontrolled symptomatic orthostatic hypotension
  9. Myocardial infarction, unstable or uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia, within 6 months prior to the first dose of study drug
  10. Any history of clinically significant sinus pauses on ECG
  11. Sinus pauses >3 seconds in the day or sinus pauses >5 seconds at night during the 48-hour pre-dose cardiac monitoring (ie, prior to first dose of study drug)
  12. Arrhythmia requiring treatment diagnosed during the 48-hour pre-dose cardiac monitoring (ie, prior to first dose of study drug). Note: subject could be reconsidered for entry into the study if appropriate treatment is obtained
  13. Hospitalized for heart failure within the 12 weeks prior to the first dose of study drug
  14. Uncontrolled infection, or active malignancy with the exception of the following:

    • Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer
    • Low risk prostate cancer with Gleason score <7 and prostate specific antigen <10 mg/mL
    • Any other cancer from which the subject has been disease-free for ≥2 years
  15. Clinically significant pleural effusion per Investigator (e.g., presence of pleural effusion ≥30% in either hemithorax)
  16. History of Grade ≥3 hypersensitivity-associated AEs or hypersensitivities to other monoclonal antibodies or the excipients found in the PRX004 formulation
  17. Known HIV infection or known hepatitis B or C virus carrier
  18. Women who are pregnant or breastfeeding
  19. Treatment with an investigational agent within 30 days or 5 half-lives (whichever is longer) prior to Month 1-Day 1
  20. Any condition which could interfere with, or the treatment for which might interfere with, the conduct of the study or which would, in the opinion of the Medical Monitor or Investigator unacceptably increase the subject's risk by participating in the study
  21. Treatment with patisiran or inotersen within 90 days or 5 halflives (whichever is longer) prior to Month 1-Day 1
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Portugal,   Spain,   Sweden,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03336580
Other Study ID Numbers  ICMJE PRX004-101
2017-003521-15 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party Prothena Biosciences Limited
Original Responsible Party Prothena Biosciences Ltd.
Current Study Sponsor  ICMJE Prothena Biosciences Limited
Original Study Sponsor  ICMJE Prothena Biosciences Ltd.
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Prothena Biosciences Limited
Verification Date August 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP